Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBITDA Margin (2019 - 2023)

Historic EBITDA Margin for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to 18760.78%.

  • ADC Therapeutics' EBITDA Margin rose 187648600.0% to 18760.78% in Q3 2023 from the same period last year, while for Sep 2023 it was 3.89%, marking a year-over-year increase of 448928300.0%. This contributed to the annual value of 2070430.86% for FY2022, which is 26867774900.0% up from last year.
  • As of Q3 2023, ADC Therapeutics' EBITDA Margin stood at 18760.78%, which was up 187648600.0% from 12819.58% recorded in Q2 2023.
  • ADC Therapeutics' 5-year EBITDA Margin high stood at 18760.78% for Q3 2023, and its period low was 439583174.87% during Q3 2021.
  • For the 5-year period, ADC Therapeutics' EBITDA Margin averaged around 31398133.41%, with its median value being 179.18% (2023).
  • Per our database at Business Quant, ADC Therapeutics' EBITDA Margin tumbled by 2000000000bps in 2021 and then soared by 2000000000bps in 2022.
  • Quarter analysis of 5 years shows ADC Therapeutics' EBITDA Margin stood at 16095.5% in 2019, then skyrocketed by 100bps to 36.16% in 2020, then plummeted by -1215754084bps to 439583174.87% in 2021, then skyrocketed by 100bps to 6.23% in 2022, then surged by 301203bps to 18760.78% in 2023.
  • Its last three reported values are 18760.78% in Q3 2023, 12819.58% for Q2 2023, and 271.55% during Q1 2023.